Following information from: https://www.medtronicdiabetes.com/treatments/continuous-glucose-monitoring
CGM that still requires finger-sticks
Continuous blood glucose monitoring (CGM) was originally designed for those with type 1 diabetes who used an insulin pump for insulin infusions during the day/night. An insulin pump releases fast- acting insulin 24 hours/day at different rates based on blood glucose. The pump has a continuous basal rate to cover blood sugar changes between meals and during sleep AND a bolus dose to cover carbohydrate intake consumed at meals/snacks.
Without CGM, a person with an insulin pump would require many finger-sticks throughout the day. With a CGM, the insulin pump would show results from the CGM and changes in dosing can be made.
This method required finger-sticks to confirm that the blood glucose read internally (from tissue fluids) by the CGM was accurate.
Even with CGM, finger-sticks remained a part of life for those with an insulin pump and CGM.
How Does CGM Work?
A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. It is connected to a transmitter that sends the information via wireless radio frequency to a monitoring and display device. The device can detect and notify you if your glucose is reaching a high or low limit. The latest Medtronic CGM systems can actually alert you before you reach your glucose limits.
Does older CGM technology replace Finger-sticks?
NO. It is recommended that you calibrate CGM systems with finger-sticks 3–4 times per day for optimal glucose sensor accuracy. CGM does require at least 1 finger-stick blood glucose reading every 12 hours to calibrate the CGM sensor1.
CGM systems usually consist of a glucose sensor, a transmitter, and a small external monitor to view your glucose levels. MiniMed insulin pumps have built-in CGM so the information can be conveniently seen on your pump screen.
The CGM monitor or insulin pump is small and easy-to-wear….but it is worn outside of the body. It can be attached to your belt, hidden in your pocket, or placed under your clothing. This component will show your current glucose levels and your historical glucose trends. It also notifies gathers your glucose data, and sends it wirelessly to the glucose monitor unit. The Medtronic transmitter is waterproof and can be worn while swimming, bathing, or showering without worries.
Components of continuous glucose monitoring
The glucose sensor is inserted under the skin to check glucose levels in tissue fluid. The glucose sensor has a small adhesive (sticky) patch to hold it in place for a few days and then it must be replaced with a new sensor. The glucose sensor is inserted with a needle, which is removed after the glucose sensor is in place. The most common place to wear a glucose sensor is in the abdomen.
The glucose sensor is easily inserted under the skin using an insertion device. A sensor is placed into the insertion device, and with a push of a button the glucose sensor is inserted quickly and easily.
Discover the Benefits of CGM
A blood glucose meter only provides a brief “snapshot” of your glucose level at a single moment in time. A CGM device, though, gives you a greater view of your glucose trends. CGM provides you with:
-The direction your glucose levels are going
-Early notification of oncoming lows and highs
-Alerts for lows or highs while you are sleeping or anytime
-Insights into how food, physical activity, medication, and illness impact your diabetes
-CGM can provide valuable information at crucial points during the day, including before and during exercise, prior to driving, before test/exam-taking, and in the middle of the night.
It is still required to check blood glucose levels with a fingerstick before therapy adjustment.
WHAT’S THE LATEST IN CGM? NO NEED FOR FINGER-STICKS!
Information from: http://www.mobihealthnews.com/content/abbotts-freestyle-libre-system-becomes-first-cgm-be-fda-cleared-use-without-fingersticks
ABBOTT FREESTYLE LIBRE CONTINUOUS GLUCOSE MONITOR….NO FINGER-STICKS!
How about a CGM that does NOT require finger-sticks? In the US, a patient will insert the CGM under the skin and for the next 10 days, blood glucose will be “checked” every 15 minutes without the need to prick a finger.
Abbott Diabetes Care’s Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to the US where Abbott is based, the approval also represents a first for continuous glucose monitoring, as it doesn’t require the user to use a fingerstick, even for calibration.
“From an emotional perspective, it’s especially important to us because Abbott’s an American company, this is a product that was designed in California, and diabetes is personal to many of us,” Abbott Research Fellow and Director of Biosensor Technology Christopher Thomas told MobiHealthNews. “Every part of the design we come to with an incredible amount of passion … so to be able to make that available in America is one of the most satisfying things that we could work for ever.”
Abbot’s Freestyle Libre fully disposable system consists of a tiny insertable sensor and a patch about the size of a quarter worn on the arm for up to 10 days (though it’s cleared for 14 in other countries). The patch records glucose data every 15 minutes. Using a special reader, the wearer can scan the patch with NFC technology, checking their glucose painlessly as often as they want. In addition to the current reading, a scan gives eight hours of historical data and trend information.
“You get where you are, where you’ve been, and where you’re going, all in that painless, one second scan,” Thomas said. “You can scan it as many times as you want per day. What we’ve done at Abbott, is we want to help this revolutionary technology to blend seamlessly into your life.”
The device is factory calibrated, which means it allows the user to eschew pricking their finger entirely. The Dexcom G5 was cleared last year for use without fingersticks, but still required them for calibration. Freestyle Libre also becomes the second CGM, after the G5, to be approved for non-adjunctive insulin dosing claims.
“The FDA is always interested in new technologies that can help make the care of people living with chronic conditions, such as diabetes, easier and more manageable,” Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health and deputy director of new product evaluation in the FDA’s Center for Devices and Radiological Health, said in a statement. “This system allows people with diabetes to avoid the additional step of fingerstick calibration, which can sometimes be painful, but still provides necessary information for treating their diabetes—with a wave of the mobile reader.”
Abbot saw a professional version of Freestyle Libre cleared one year ago. That device was nearly identical, but only a healthcare provider could scan it and view the glucose data. The newest clearance allows users to view data themselves, something that research shows they’re keen to do often — an average of 16 times per day.
Looking to Europe, where the device has been available for some time, we can make some predictions about next steps for Freestyle Libre in the US. For one thing, the sensor will likely be expanded from 10 to 14 days of wear.
Also in Europe, Abbott has incorporated smartphone apps into the operation of the system. Users with Android phones that have RFID or NFC technology can leave the reader at home and scan the sensor directly with their phones. There are also monitoring apps for both care providers and parents to see someone else’s data remotely.
“We’ve got a long pipeline of innovations that are coming,” Thomas said. “Stay tuned for different changes to that, smartphone editions, it’s all part of the exciting pipeline that we’re working on right now.”